Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

20 trials with published results (7%)

Research Maturity

110 completed trials (38% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.4%

7 terminated out of 291 trials

Success Rate

94.0%

+7.5% vs benchmark

Late-Stage Pipeline

6%

17 trials in Phase 3/4

Results Transparency

18%

20 of 110 completed with results

Key Signals

20 with results94% success

Data Visualizations

Phase Distribution

190Total
Not Applicable (66)
Early P 1 (26)
P 1 (65)
P 2 (16)
P 3 (8)
P 4 (9)

Trial Status

Completed110
Recruiting80
Unknown44
Not Yet Recruiting26
Withdrawn9
Active Not Recruiting7

Trial Success Rate

94.0%

Benchmark: 86.5%

Based on 110 completed trials

Clinical Trials (291)

Showing 20 of 20 trials
NCT06948110RecruitingPrimary

Deciphering the Genetic Architecture of Autoimmune Diseases

NCT05418101Phase 1CompletedPrimary

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

NCT06342713Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT02682511Phase 2Active Not Recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT01351545Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT04593888Not ApplicableActive Not Recruiting

Gluten Reduction and Risk of Celiac Disease

NCT07507201Early Phase 1RecruitingPrimary

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

NCT01420133Not ApplicableCompletedPrimary

Is a Diet Necessary When Corticosteroid Treatment is Prescribed?

NCT04094259CompletedPrimary

Alternative Care in Patients With Auto-Immune Diseases

NCT05789030Not ApplicableRecruitingPrimary

Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement

NCT07490951Not ApplicableNot Yet RecruitingPrimary

Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases

NCT06747156Early Phase 1RecruitingPrimary

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

NCT05969821Not Yet Recruiting

Clonal Hematopoiesis of Immunological Significance

NCT06375993Phase 1Enrolling By Invitation

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

NCT06688799Phase 1RecruitingPrimary

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

NCT07143617Not ApplicableRecruitingPrimary

Exploratory Clinical Study on the Safety of STR-P004

NCT07455578Phase 1Not Yet RecruitingPrimary

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT01758042Not ApplicableCompleted

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT06548607Early Phase 1Recruiting

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

NCT07408336Early Phase 1RecruitingPrimary

Clinical Study of AFN50 Injection in the Autoimmune Diseases

Scroll to load more

Research Network

Activity Timeline